VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

May 16, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-05-15

Reporting Person: MUELLER PETER (EVP, Global R&D, CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-15	Common Stock	M	6500	$16.32	Acquired	138816	Direct
2012-05-15	Common Stock	S	2100	$63.84	Disposed	136716	Direct
2012-05-15	Common Stock	S	3700	$64.30	Disposed	133016	Direct
2012-05-15	Common Stock	S	700	$65.50	Disposed	132316	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-05-15	Stock Option	$16.32	M	6500	Disposed	2013-07-14	Common Stock (6500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4367	Indirect
Common Stock	15920	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $63.84 (range $63.63 to $63.99).

F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $64.30 (range $64.01 to $64.85).

F5: Open market sales reported on this line occurred at a weighted average price of $65.50 (range $65.00 to $65.93).

F6: Common stock held in grantor retained annuity trusts.